Please login to the form below

Not currently logged in


This page shows the latest volanesorsen news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca and Ionis sign $3.6bn deal for eplontersen

AstraZeneca and Ionis sign $3.6bn deal for eplontersen

It currently has three marketed products – Spinraza (nusinersen) for spinal muscular atrophy, Tegsedi (inotersen) for ATTR and Waylivra (volanesorsen) for familial chylomicronaemia syndrome – as well as ‘a premier late-stage pipeline’.

Latest news

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Subscribe to our email news alerts


Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (, a trusted independent medical education website. Support...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...